You have read all your free articles, to continue reading subscribe to read the rest of this content.
LIDDS has received approval from authorities in Lithuania to conduct its Phase I study, NZ-DTX-001. The aim of the phase I dose escalation clinical trial is to assess the tolerability and safety of intratumoral injections of NanoZolid with docetaxel, a well-established cytostatic used in the treaAlready a subscriber Login You…
Together with LTS Lohmann Therapie-Systeme the company will start the first-ever clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efAlready a subscriber…
Affibody, ACELYRIN, and Inmagene Biopharmaceuticals, have announced that a 16-week, global, Phase 2 clinical trial of izokibep in patients with psoriatic arthritis (PsA) met its primary endpoint in a pre-specified interim analysis. The double-blind, placebo-controlled Phase 2 clinical trial, desiAlready a subscriber Login You have read all your free articles,…
BioInvent International has announced that a fourth complete response has been observed in the 100 mg dose expansion cohort in the IV arm of the Phase 1/2 trial of its lead drug candidate BI-1206, the novel anti-FcgRIIB antibody, in combination with rituximab in non-Hodgkin’s lymphoma (NHL). ThAlready a subscriber Login…
